{"prompt": "['adverse events.', '14.5', 'Accrual/Study Duration Considerations', 'Based on patient accrual in previous RTOG legacy/NRG Oncology studies, the initial 6', 'months accrual is projected to be negligible while institutions are obtaining IRB', 'approval. This protocol has a similar patient population (post-prostatectomy) to RTOG', '0534. The accrual rate for the QOL component on that study was 11.3 patients per', 'month. Therefore, the projected accrual rate is 11 patients per month. Based on this', 'information, it is projected that the study will complete accrual in about 26 months from', 'the end of the 6-month period of negligibility (32 months from activation). The primary', 'endpoint analysis will occur approximately 5 years from study activation. Accrual will be', 'monitored in accordance to CTEP accrual guidelines.', '14.6', 'Secondary Enppoints', '14.6.1 Secondary Hypotheses and Endpoints:', '1. Hypofractionated postprostatectomy radiotherapy (HYPORT) delivering 62.5 Gy in', '25 fractions of 2.5 Gy to the prostate bed is not associated with excess patient-', 'reported GI symptoms compared to conventionally fractionated postprostatectomy', 'radiotherapy (COPORT) delivering 66.6 Gy in 37 fractions of 1.8 Gy to the prostate', 'bed at the end of RT, and 6 months, 1 and 5 years from the start of RT.', '2. HYPORT delivering 62.5 Gy in 25 fractions of 2.5 Gy to the prostate bed is not', 'associated with excess patient-reported GU symptoms compared to COPORT', 'delivering 66.6 Gy in 37 fractions of 1.8 Gy to the prostate bed at the end of RT, and', '6 months, 1 and 5 years from the start of RT.', '3.', 'Comparison of freedom from biochemical failure (FBF) between the HYPORT arm', 'and COPORT arm.', '4. Comparison of time to progression (TTP) where progression is defined as the first', 'occurrence of, BF, local failure, regional failure, distant metastasis (DM), initiation of', 'new unplanned anticancer treatment, or death from prostate cancer (PCSM) between', 'the HYPORT arm and COPORT arm.', '5. Comparison of local failure, regional failure, salvage therapy (i.e. initiation of new', 'unplanned anticancer treatment), DM, PCSM, and os rates between the HYPORT arm', 'and COPORT arm.', '6. HYPORT is not associated with excess adverse events (AEs) compared to COPORT', '14.6.2 Definitions of Secondary Endpoints and How These Will Be Analyzed', 'Additional EPIC Enppoints', 'All four domains of the EPIC will be analyzed, bowel, urinary, sexual, and hormonal. The', 'change scores, calculated as baseline score subtracted from follow-up score, will be', 'analyzed using a t-test. If the data are determined to be non-normal, a Wilcoxon test may', 'be used instead. The follow-up timepoints of interest are end of RT, 6 months, 1, 2 (for', 'sexual and hormonal domains) and 5 years from the start of treatment. A longitudinal', 'analysis incorporating all follow-up time points, will be conducted separately for each', 'domain score using a general linear model with maximum likelihood estimation, adjusting', 'for baseline domain score, treatment arm, Gleason score, baseline PSA, T-stage, age, and', 'NRG-GU003', '45', 'Version Date: April 26, 2019']['race. These analyses will be conducted regardless the outcomes of the primary t-test. For', 'the comparison of primary endpoints at 2 years adjusting for other variables using the', 'longitudinal model, especially stratification variables, the results will be similar to those of', 'the primary analysis in general. In the rare case when it is different, we will examine very', 'carefully the impact of missing data and the adjusted variables and make a meaningful', 'conclusion regarding the outcome.', 'If any of the domains are found to significantly differ between arms, then analysis of that', \"domain's subscales will be undertaken to assess which particular subscale is driving the\", 'significant difference. The subscales are function both incontinency and', 'rritative/obstructive for the urinary domain, and function and bother for the bowel, sexual,', 'and hormonal domains.', 'Prior to performing analyses, an evaluation of the amount, reasons and patterns of missing', 'data will be performed, using the well-known categories of missing completely at random', '(MCAR), missing at random (MAR) and missing not at random (MNAR) (Fairclough', '2010, Verbeke 2000). If>15% of the data is missing at any time point for the EPIC bowel', 'and urinary domain scores, patient characteristics will be compared between patients with', 'completed assessments and those with missing assessments. If any are found to differ', 'significantly, they will be included in the mixed effects model which assumes that the data', 'is MAR. If the missingness is determined to be non-ignorable, other methods may be', 'performed. Specifically, a joint model that allows a shared parameter between the repeated', 'measurements and time to death or drop out can be used if considered MNAR due to the', 'high number of patient deaths or dropouts (Rizopoulos 2012). Other options for MNAR', 'data are pattern mixture and selection models (Fairclough 2010, Little 1995). Sensitivity', 'analyses will be performed to compare the results of different analytic strategies', '(Fairclough 1998).', 'Secondary Efficacy Enppoints', 'os is defined as a death from any cause and will be measured from the date of', 'randomization to the date of death. BF is defined as a PSA > 0.4 ng/mL and rising (i.e.', 'PSA > 0.4 1 ng/mL followed by a value higher than the first by any amount) or followed by', 'inititation of salvage hormones. The time of the first occurrence of PSA > 0.4 ng/mL will', 'be considered the event time. An alternative definition of BF will also be assessed: PSA >', 'PSA nadir + 2 ng/mL where nadir is the lowest post-RT PSA value. PCSM will be', 'measured from the date of randomization to the date of death due to prostate cancer. LF is', 'defined as the development of a new biopsy-proven mass in the prostate bed after', 'enrollment in the protocol and will be measured from the date of randomization to the date', 'of documented local failure. RF will be defined as radiographic evidence (CT or MRI) of', 'lymphadenopathy (lymph node size > 1.0 cm in the short axis) in a patient without the', 'diagnosis of a hematologic/lymphomatous disorder associated with adenopathy and will', 'be measured from the date of randomization to the date of documented regional metastasis.', 'DM is defined as radiographic evidence of hematogenous spread (e.g., bone scan, CT,', 'MRI) and will be measured from the date of randomization to the date of documented DM.', 'For LF, RF, and DM, a BF is required prior to the LF, RF, and DM but will not be', 'NRG-GU003', '46', 'Version Date: April 26, 2019']\n\n###\n\n", "completion": "END"}